Mangoceuticals, Inc. (MGRX) Stock Analysis
A live, multi-source view of Mangoceuticals, Inc. (MGRX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Mangoceuticals, Inc.
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Sector: Healthcare · Industry: Health Information Services · United States · 3 employees · mangoceuticals.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Mangoceuticals, Inc. (MGRX) had a market capitalization of $8.9M; the shares traded in a 52-week range of $0.16 – $2.75 (-82.7% over the year).
- Market cap
- $8.9M
- Enterprise value
- $8.9M
- Price / book
- 0.59
- EPS (trailing)
- $-1.00
- Payout ratio
- 0.0%
- 52-week range
- $0.16 – $2.75
- 52-week change
- -82.7%
- Average volume
- 13.6M
- Shares outstanding
- 21.6M
- Short % of float
- 9.13%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Mangoceuticals, Inc. (MGRX) last closed at $0.42 (the last completed close before that scan).
Technicals at the scan: RSI 48 (neutral territory), price -3.3% versus its 20-day average, 20-day versus 50-day average spread -2.3%, MACD histogram -0.00.
Sentiment inputs: StockTwits 53% bullish.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for MGRX in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
MGRX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Mangoceuticals, Inc. (MGRX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MGRX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.